| Affiliation: | 1.Medical Oncology Service, Institut Català d’Oncologia,Hospital Universitari Germans Trias i Pujol,Badalona (Barcelona),Spain;2.Cancer Research Programm,IMIM (Hospital del Mar Medical Research Institute),Barcelona,Spain;3.Medical Oncology Service,Hospital Universitario,Madrid,Spain;4.Medical Oncology Service,Hospital Clinic Provincial,Barcelona,Spain;5.Medical Oncology Service,Hospital del Mar,Barcelona,Spain;6.Medical Oncology Service,Hospital de Sant Pau,Barcelona,Spain;7.Medical Oncology Service,Hospital Universitario Virgen de las Nieves,Granada,Spain;8.Medical Oncology Service,Institut Català d’Oncologia-IDIBELL,Hospitalet de Llobregat,Spain;9.Medical Oncology Service, Institut Català d’Oncologia,Hospital Josep Trueta,Girona,Spain;10.Medical Oncology Service,Hospital Miguel Servet,Saragossa,Spain;11.Medical Oncology Service,Hospital General Universitario de Valencia,Valencia,Spain;12.Medical Oncology Service,Hospital Universitario Clínico San Carlos,Madrid,Spain;13.Medical Oncology Service,Hospital Provincial de Castellón,Castellón,Spain;14.Radiation Oncology Service, Institut Català d’Oncologia,Hospital Josep Trueta,Girona,Spain;15.Medical Oncology Service,Hospital Universitario La Fe,Valencia,Spain;16.Institut Investigació Germans Trias i Pujol (IGTP),Hospital Germans Trias i Pujol,Badalona,Spain;17.Clinical and Translational Oncology Group,Clínica del Country,Bogotá,Colombia;18.Foundation for Clinical and Applied Cancer Research, FICMAC,Bogotá,Colombia;19.Biology Systems Department,Universidad el Bosque,Bogotá,Colombia;20.Radiation Oncology Service,Hospital Clinic Provincial,Barcelona,Spain;21.Radiation Oncology Service, Institut Català d’Oncologia,Hospital Universitari Germans Trias i Pujol,Badalona,Spain |
| Abstract: | PurposeWe retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients.Patients and methodsWe compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy.ResultsOS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P?=?0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P?=?0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P?=?0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor.ConclusionIn our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy. |
